40.05
+6.66%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pell Bio Med Technology Co
Its shares trade on Taiwan Stock Exchange under the ticker 6949.TW. It has been listed since 8 March 2024. In the fiscal year to 31 December 2025, it reported revenue of TWD 31.4m and a net loss of TWD 423.9m. At that date it held total assets of TWD 2.11bn and shareholders' equity of TWD 1.42bn.
Pell Bio Med Technology Co Ltd is a TW-based company operating in industry. The company is headquartered in Taipei City, Taipei. The company went IPO on 2024-03-08. Pell Bio Med Technology Co Ltd is a Taiwan-based trading company mainly engaged in the immune genetic engineering and the development of non-genetically modified cell therapy products and non-cell products. The main business focuses on immune cell therapy that uses genetic engineering to modify the patient's own immune cells. The firm is engaged in the development of chimeric antigen receptor T cell therapy for the treatment of B-cell lymphoma PL001. Non-genetically modified cell therapy products include cytokine-induced killer cells (CIK), and mixed cells using a combination of dendritic cells and cytokine-induced killer cells (DC-CIK). Non-cell products include hair care products and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 8 Mar 2024
- Website
- pellbmt.com ↗
Leadership
Pay as last reported
- Mr. Changmin WuHead of Finance & Accounting, Corporate Governance Officer
- Jiancheng GuoDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pell Bio Med Technology Co Ltd focuses on immune genetic engineering and non-GMO cell therapy products in Taiwan.
- The company develops chimeric antigen receptor T cell therapy for B-cell lymphoma PL001 treatment.
- Pell Bio Med Technology Co Ltd offers non-cell products like hair care and immune cell therapy solutions.
Weaknesses
- The company's business is limited to immune cell therapy and non-cell products in Taiwan.
- Pell Bio Med Technology Co Ltd has no mention of international expansion plans.
- The firm's focus on immune genetic engineering may limit diversification in the health sector.
Opportunities
- The growing demand for immune cell therapy in the health care sector presents opportunities.
- Pell Bio Med Technology Co Ltd can expand its non-cell products like hair care in new markets.
- The company may leverage its PL001 therapy for broader applications in cancer treatment.
Threats
- Competition in the immune cell therapy market could impact Pell Bio Med Technology Co Ltd's growth.
- Regulatory challenges in the health care industry may affect product development.
- The company's reliance on immune genetic engineering could pose risks if trends shift.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.